Liraglutide 1.8 mg/day vs. 0.9 mg/day efficacy and safety compared in Japanese T2DM

Type 2 Diabetes Mellitus (T2DM) is a chronic metabolic disorder characterized by insulin resistance and impaired insulin secretion, leading to hyperglycemia. Effective management is crucial to prevent long-term complications like cardiovascular disease, nephropathy, and retinopathy. Liraglutide, a GLP-1 receptor agonist, is an established treatment for T2DM, improving glycemic control and offering cardiovascular benefits. Dosing regimens vary, and understanding optimal efficacy and safety profiles across different populations, such as Japanese subjects, is important for personalized medicine. This trial aims to refine dosing strategies.

This trial was designed to compare the efficacy and safety of two different daily doses of Liraglutide in Japanese subjects with Type 2 Diabetes Mellitus. Participants were randomized to receive either Liraglutide 1.8 mg/day or Liraglutide 0.9 mg/day. The primary endpoints likely included changes in glycemic parameters like HbA1c, fasting plasma glucose, and body weight, along with comprehensive safety and tolerability assessments. The study aimed to determine if the higher dose offered superior benefits without an unacceptable increase in adverse events within this specific population.